Officials rush to defend AstraZeneca Covid vaccine after UK, EU blood clot guidance


Sumary of Officials rush to defend AstraZeneca Covid vaccine after UK, EU blood clot guidance:

  • UK Prime Minister Boris Johnson poses for a photograph with a vial of the AstraZeneca/Oxford University Covid-19 candidate vaccine..
  • The British government and health experts in the country have rushed to defend the coronavirus vaccine developed by AstraZeneca and the University of Oxford following concerns over a possible link to blood clots..
  • On Wednesday, the U.K.’s health and vaccine regulators issued a change of guidance over who should receive the shot..
  • They now recommend that anyone under the age of 30 should receive an alternative vaccine amid concerns that it could, in rare circumstances, lead to a serious blood clot..
  • Following a safety review of the AstraZeneca vaccine, sparked by concerns over reports of rare blood clotting disorders in a small number of vaccinated individuals, both the U.K..
  • However, amid concerns that the reputation of the vaccine could be damaged further, experts have rushed to defend it – and one Twitter user commented that officials appeared to have gone into “damage limitation”.
  • He said the safety measures surrounding the vaccine were robust and enabled regulators to “spot this extremely rare event.”.
  • “The safety system that we have around this vaccine is so sensitive that it can pick up events that are four in a million – I’m told this is about the equivalent risk of taking a long-haul flight.”.
  • Prime Minister Boris Johnson, who has received a first shot of the vaccine himself, said that “the best thing people should do is look at what the MHRA say, our independent regulator – that’s why we have them, that’s why they are independent..
  • It comes amid growing concerns that Wednesday’s announcement could lead to vaccine hesitancy in Britain, where the immunization program has gone well so far, with over 31.7 million adults having received a first dose of a vaccine, to date..
  • has been working through priority groups for a vaccine, with the under-50s (without underlying health conditions) next in line for a shot..
  • England’s Deputy Chief Medical Officer Jonathan Van-Tam also sought to downplay concerns on Wednesday, saying that the reports of blood clots were “vanishingly rare.”.
  • He also noted that “changes in preference for vaccines are business as usual and this is a course correction.”.
  • Vaccine hesitancy ‘clearly a concern’ Andrew Freedman, reader in infectious diseases at Cardiff University School of Medicine, was among the experts saying the move by the U.K..
  • “It does sound like a sensible decision based on the evidence we have so far of a probable causal link between the AZ vaccine and these very rare thrombotic side effects that have been noted,”.
  • Meanwhile, Andrew Pollard, professor of pediatric infection and immunity at the University of Oxford, which developed the shot along with AstraZeneca, said in a statement Wednesday that “safety has been our priority throughout the development of the vaccine …..

Want to know more click here go to source.

From -
Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages

Site Language

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.